Novo A/S was established in 1999 and is fully owned by the Novo Nordisk Foundation, an independent Danish foundation with corporate interests and a history going back to 1923.
Novo A/S oversees, invests and manages the assets of the Novo Nordisk Foundation valued at more than EUR 47 billion.
Besides being the controlling shareholder in the Novo Group companies, including Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies within life science, as well as manages a broad portfolio of financial assets.
As an international investor, we work out of Copenhagen, San Francisco, Boston and London. Our team of scientific and commercial experts actively support our portfolio of projects and companies and manage our range of financial investments.